The topoisomerase II-Hsp90 complex: A new chemotherapeutic target?

International Journal of Cancer

Volumn 118, Issue 11, 2006, Pages 2685-2693

  Barker, Catherine R ^a   Hamlett, Jane ^a   Pennington, Stephen R ^b   Burrows, Francis ^c   Lundgren, Karen ^c   Lough, Rachel ^c   Watson, Alastair J M ^a   Jenkins, John R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c BIOGEN   (United States)

Author keywords

Chemotherapy; Hsp90; Protein protein interactions; Topoisomerase II

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MITOXANTRONE; RADICICOL; SULFORHODAMINE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA MODIFICATION; DRUG TARGETING; FEMALE; GEL ELECTROPHORESIS; IMMUNOPRECIPITATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MITOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BENZOQUINONES; BREAST NEOPLASMS; CARCINOMA, ADENOSQUAMOUS; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE II; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME INHIBITORS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; LACTONES; MACROLIDES; MICE; MICE, NUDE; MOLECULAR CHAPERONES; NEOPLASMS; PROTEIN BINDING; QUINONES; RIFABUTIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33646338628     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21717     Document Type: Article

References (42)

1. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996;379:225-32.
2. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
3. Mondal N, Parvin JD. DNA topoisomerase IIα is required for RNA polymerase II transcription on chromatin templates. Nature 2001;413:435-8.
4. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 1988;85:7177-81.
5. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID. Isolation of cDNA clones encoding the β-isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 1992;20:5587-92.
6. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH- 3T3 cells. Cell Growth Differ 1991;2:209-14.
7. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003;3:321-38.
8. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, Nitiss JL. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J Biol Chem 2000;275:2137-46.
9. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003;99:167-81.
10. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 1998;273:17643-50.
11. Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK. Mitotic phosphorylation of DNA topoisomerase IIα by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem. 2000;275:34710-8.
12. Wells NJ, Fry AM, Guano F, Norbury C, Hickson ID. Cell cycle phase-specific phosphorylation of human topoisomerase IIα. Evidence of a role for protein kinase C. J Biol Chem 1995;270:28357-63.
13. Cowell IG, Okorokov AL, Cutts SA, Padget K, Bell M, Milner J, Austin CA. Human topoisomerase IIα and IIβ interact with the C-terminal region of p53. Exp Cell Res 2000;255:86-94.
14. Kwon Y, Shin BS, Chung IK. The p53 tumour suppressor stimulates the catalytic activity of human topoisomerase IIα by enhancing the rate of ATP hydrolysis. J Biol Chem 2000;275:18503-10.
15. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumour suppressor. Mol Cell Biol 1997;17:389-97.
16. Watt PM, Hickson ID, Boris RH, Louis EJ. SGS1, a homologue of the Bloom's and Werner's syndrome genes, is required for maintenance of genome stability in Saccharomyces cerevisiae. Genetics 1996;144:935-45.
17. Yamagata K, Kato J, Shimamoto A, Goto M, Furuichi Y, Ikeda H. Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast sgs1 mutant: implication for genomic stability in human diseases. Proc Natl Acad Sci USA 1998;95:8733-8.
18. Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003;3:297-300.
19. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
20. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIα by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999;180:97-104.
21. Tallarida RJ, Stone DJ, Jr, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sciences 1997;61:417-25.
22. Tallarida RJ. The interaction index: a measure of drug synergism. Pain 2002;98:163-8.
23. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001;154:267-73.
24. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
25. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localisation of heat shock protein in human tumour cells. Int J Cancer 1992;51:613-19.
26. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:357-9.
27. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24.
28. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FC1, a specific inhibitor of tumour Hsp90. Chem Biol 2004;11:787-97.
29. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
30. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:962-6.
31. Zuo J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94:471-80.
32. Guo Y, Guettouche T, Fenna M, Boellmann F, Pratt WB, Toft DO, Smith DF, Voellmy R. Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J Biol Chem 2001;276:45791-9.
33. Sato N, Yamamoto T, Sekine Y, Yumioka T, Junicho A, Fuse H, Matsuda T. Involvement of heat-shock protein 90 in the interleukin-6-mediated signalling pathway through STAT3. Biochem Biophys Res Commun 2003;300:847-52.
34. Boudeau J, Deak M, Lawler MA, Morrice NA, Alessi DR. Heat-shock protein 90 and Cdc37 interact with LKBI and regulate its stability. Biochem J 2003;370:849-57.
35. Furukawa M, Uchiumi T, Nomoto M, Takano H, Morimoto RI, Naito S, Kuwano M, Kohno K. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIα gene by heat shock. J Biol Chem 1998;273:10550-5.
36. Ratten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005;280:14349-55.
37. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukaemia cells to cytotoxic chemotherapy. Leukemia 2001;15:1537-43.
38. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
39. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998;273:3679-86.
40. Redmond T, Sanchez ER, Bresnick EH, Schlesinger MJ, Toft DO, Pratt WB, Welsh MJ. Immunofluorescence colocalization of the 90-kDa heat-shock protein and microtubules in interphase and mitotic mammalian cells. Eur J Cell Biol 1989;50:66-75.
41. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-6.
42. Shah M, Patel K, Fried VA, Sehgal PB. Interaction of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signalling during fever. J Biol Chem 2002;277:45662-9.